1. 江苏省南通市第三人民医院,江苏,南通,226006
2. 南京中医药大学第一临床医学院,江苏,南京,210046
3. 江苏省南通市第六人民医院,江苏,南通,226011
扫 描 看 全 文
邵建国, 何红梅, 陈琳, 等. 清脂护肝方对非酒精性脂肪肝大鼠肝组织中Hck、Lyn、Fgr、SSeCKS表达的影响[J]. 上海中医药杂志, 2015,49(2):68-73.
SHAO Jian-guo, HE Hong-mei, CHEN Lin, et al. Effect of “Qingzhi Hugan Prescription” on the expressions of Hck, Lyn, Fgr and SSeCKS in liver tissues of rats with nonalcoholic fatty liver disease[J]. Shanghai Journal of Traditional Chinese Medicine, 2015,49(2):68-73.
邵建国, 何红梅, 陈琳, 等. 清脂护肝方对非酒精性脂肪肝大鼠肝组织中Hck、Lyn、Fgr、SSeCKS表达的影响[J]. 上海中医药杂志, 2015,49(2):68-73. DOI:
SHAO Jian-guo, HE Hong-mei, CHEN Lin, et al. Effect of “Qingzhi Hugan Prescription” on the expressions of Hck, Lyn, Fgr and SSeCKS in liver tissues of rats with nonalcoholic fatty liver disease[J]. Shanghai Journal of Traditional Chinese Medicine, 2015,49(2):68-73. DOI:
目的:观察不同剂量清脂护肝方对非酒精性脂肪肝(NAFLD)大鼠肝组织中Src家族相关激酶(Hck、Lyn、Fgr)和Src抑制的蛋白激酶C底物(SSeCKS)表达的影响,探讨其治疗NAFLD的作用机制 方法:2月龄SD大鼠58只,除正常组12只大鼠外,其余大鼠均喂养高脂饲料(80.5%普通饲料、2%胆固醇、12%猪油、5%蛋黄粉、0.5%胆酸钠),8周后随机抽取6只验证非酒精性脂肪肝大鼠造模是否成功;将造模成功的大鼠再随机分为模型组,清脂护肝方高、中、低剂量组,每组10只。清脂护肝方高、中、低剂量组予相应清脂护肝方药液灌胃6周,模型组和正常组以0.9%NaCl溶液灌胃6周。实验结束后用免疫组织化学(IHC)法检测大鼠肝组织中Hck、Lyn、Fgr、SSeCKS的表达及其相关关系 结果:与正常组比较,模型组SSeCKS、Hck、Lyn表达差异均有统计学意义(P<0.01)。与模型组比较,清脂护肝高、中、低剂量组Hck、Lyn表达差异均有统计学意义(P<0.01),清脂护肝低、中剂量组SSeCKS表达差异有统计学意义(P<0.05,P<0.01)。清脂护肝方对Fgr的表达无明显影响(P>0.05) 结论:清脂护肝方能够调控SSeCKS、Lyn、Hck的表达从而减轻肝脏的炎症反应,是清脂护肝方治疗非酒精性脂肪肝的机制之一。
Objective: To observe the effects of different doses of “Qingzhi Hugan Prescription” on the expressions of Src family kinase (Hck, Lyn, Fgr) and Src-suppressed C kinase substrate in liver tissues of rats with nonalcoholic fatty liver disease, and to investigate its mechanism on NAFLD Methods: Fifty-eight SD rats of two months were classified into normal group, except the normal group, others were feed with high-fat (80.5% ordinary fodder, 2% cholesterol, 12% lard, 5% egg yolk powder, 0.5% sodium cholic acid) for 8 weeks and the models were established. The models were randomized into model group, “Qingzhi Hugan Prescription” groups (large, medium and small dose). “Qingzhi Hugan Prescription”groups were gavaged with decotions, and the model group ang normal group was gavaged with 0.9% NaCl solution. After the experiment, the expressions of Hck, Lyn, Fgr and SSeCKS of the liver tissues were detected by immunohistochemistry Results: Compared with model group, whatever the large, medium and small dose of the Chinese medicine groups, especially the large dose of “Qingzhi Hugan Prescription” group, the positive expressions of Hck and Lyn were decreased markedly (P<0.01); compared with the normal group, the expression of SSeCKS in the model group was decreased markedly; in the Chinese medicine groups, the SSeCKS were expressed between the model group and normal group; It showed a trend of decrease along with the rise of the expressions of Lyn and Hck in the rat liver tissue with nonalcoholic fatty liver disease;Compared with model group, effect of “Qingzhi Hugan Prescription” on the expression of Fgr was insignificant (P>0.05) Conclusion: Expressions of SSeCKS, Lyn and Hck were regulated by “Qingzhi Hugan Prescription”, which reduced inflammation of the liver. It can be used as one of the mechanisms for the treatment of NAFLD.
清脂护肝方非酒精性脂肪肝大鼠
“Qingzhi Hugan Prescription”non-alcohlic fatty liver disease(NAFLD)rat
0
浏览量
162
下载量
0
CSCD
4
CNKI被引量
关联资源
相关文章
相关作者
相关机构